Andrea Feigl is a visiting scientist and health economist at Harvard TH Chan School of Public Health and Senior Health Economist at Microclinic International. She also serves as scientific advisor to the Lancet Commission on Non-Communicable Diseases, Injuries, and Poverty. Previously, she served as health economist and policy analyst with the Organisation for Economic Cooperation and Development (OECD). At Harvard, Andrea is leading an SDG3-focused multisector initiative, focused on innovative health financing for neglected global health issues and multisector health diplomacy. Her academic work focuses on health systems financing and governance, universal healthcare, and cost-effectiveness of chronic disease interventions in developing countries. She led the largest worldwide longitudinal analysis of the political, social, and economic determinants of universal healthcare in 196 countries (published in Health Policy), leading the impact evaluation of a nationwide anti-smoking legislation in Chile (published in WHO Bulletin), and led the impact study of the award-winning intervention program for obesity/diabetes prevention in Amman, Jordan (project awarded Global Health Project of the Year from Consortium of Universities for Global Health).